1-3 of 3
Erkut Bahceci
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular profile of FLT3 -mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2144–2155.
https://doi.org/10.1182/bloodadvances.2021006489
Published: 2022
Includes: Supplemental data
Journal Articles

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Clinical Trials & Observations
Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2020) 4 (3): 514–524.
https://doi.org/10.1182/bloodadvances.2019000919
Published: 2020
Includes: Supplemental data
Journal Articles

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3 -ITD mutations

Clinical Trials & Observations
Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller
Journal: Blood Advances
Blood Adv (2018) 2 (8): 825–831.
https://doi.org/10.1182/bloodadvances.2018015925
Published: 2018
Includes: Supplemental data